drug_type
RELEVANT_DRUG
intervention_type
Antibody–drug conjugate (targeted cytotoxic therapy)
drug_description
An antibody–drug conjugate targeting TROP2 that delivers a topoisomerase I inhibitor (DXd) to TROP2-expressing tumor cells, causing DNA damage and tumor cell death with a potential bystander effect.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized anti‑TROP2 monoclonal antibody linked via a cleavable linker to the topoisomerase I inhibitor DXd. After binding TROP2 on tumor cells, the ADC is internalized and the payload is released to inhibit topoisomerase I, inducing DNA damage and tumor cell death; the membrane‑permeable payload can produce a bystander killing effect.
drug_name
Datopotamab deruxtecan (Dato-DXd)
nct_id_drug_ref
NCT06508216